Phase 1 Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with either Type 1 or Type 2 Diabetes.
- People whose reduced vision is mainly caused by diabetic macular oedema (swelling in the central part of the retina caused by diabetes).
- People whose eye scan results show a specific level of retinal swelling in the central area — the exact measurements differ depending on sex and the type of scanning machine used (confirm with trial site).
- People whose vision test results fall within a specific range on a standardised eye chart called the ETDRS chart — not too severely reduced, but not near-normal either (confirm with trial site).
- People whose eyes are clear enough, and who are able to cooperate sufficiently, to allow good-quality retinal photos and scans to be taken.
- People who have either never had anti-VEGF injections into the eye, or who have had at least 2 anti-VEGF injections close together (less than 7 weeks apart) without the retinal swelling fully resolving — with the most recent injection given at least 6 weeks before the start of the study.
Who may not be able to join:
- People with any eye condition that blocks a clear view of the retina, such as a significant cataract or bleeding inside the eye.
- People with high blood pressure that is not well controlled.
- People with glaucoma that is not well controlled.
- People who have another eye disease in the eye being studied, beyond the diabetic macular oedema.
- People who have had steroid injections in or around the eye being studied within the past 3 months.
- People who have had any eye surgery in the eye being studied within the past 3 months.
- People whose diabetes is poorly controlled, specifically those with a blood sugar marker (HbA1c) of 10% or higher.
- People who have a history of the retina detaching in the eye being studied, or other blood vessel diseases affecting the retina in that eye.
- People who have had a certain type of laser treatment to the retina in the eye being studied within the past 3 months.
- People who have an inherited retinal disease, or a history of an advanced form of diabetic eye disease called proliferative diabetic retinopathy.
- People with a moderate-to-severe stage of kidney disease (stage 3b or worse).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Huma Qamar, MD, MPH, CMI, Ocugen
Phone: 845-664-1505
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Study Drug-related adverse events (SDAE); Treatment-emergent adverse events (TEAEs); Serious adverse events (SAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.